Allena Ji on the challenges of targeted biomarker quantitation by LC–MS
In this interview, Allena Ji (Sanofi Genzyme; MA, USA) discusses the advantages and challenges of using triple quadrupole mass spectrometry, the challenges associated with increasing biomarker assay sensitivity and how the field may be regulated and standardized.
Related articles:
- Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
- Validated UHPLC–MS/MS method for quantification of doxycycline in abdominal aortic aneurysm patients
- 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 – LBA: immunogenicity, biomarkers and PK assays)
If you liked this interview, you might also like:
Novel ADME biomarkers and HRMS move new medicines to patients faster
Pegah Jalili’s insight into biomarker discovery
LC–MS for biotherapeutics research: an interview with Timothy Olah
